CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 355448-355562 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/932bcdd2f6c6d487386e8bf983e4874387771be1","sourcedb":"CORD-19","sourceid":"932bcdd2f6c6d487386e8bf983e4874387771be1","text":"Treatment with neutralizing anti-IL-16 antibody successfully reversed paralysis and ameliorated relapsing disease.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T33181","span":{"begin":0,"end":114},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T33181","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T174","span":{"begin":0,"end":114},"obj":"Sentence"}],"attributes":[{"subj":"T174","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-HP","denotations":[{"id":"T621","span":{"begin":70,"end":79},"obj":"Phenotype"}],"attributes":[{"id":"A621","pred":"hp_id","subj":"T621","obj":"http://purl.obolibrary.org/obo/HP_0003470"},{"subj":"T621","pred":"source","obj":"CORD-19-PD-HP"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ec93e3","default":true},{"id":"CORD-19_Custom_license_subset","color":"#93ecdb"},{"id":"CORD-19-PD-HP","color":"#ecc193"}]}]}}